Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT06767800RecruitingPhase 2
Study of TQB2102 with immunotherapy for HER2-positive gastroesophageal cancer
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
Fuyang, AnhuiAges 18–75 - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT06769685Enrolling by invitation
Platelet-boosting drug for solid tumor patients with low platelets
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
Jinhua, ZhejiangAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+ - NCT06755515Enrolling by invitationPhase 2/Phase 3
Rulonilimab + Chemo for Advanced Cervical Cancer
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
Linyi, ShandongAges 18 years+ - NCT06747585RecruitingPhase 1/Phase 2
ALE.P02 for advanced squamous cell cancers with CLDN1
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06736379RecruitingPhase 1
Injected immune therapy for head and neck cancer
This trial tests an experimental treatment that is injected directly into the tumor to stimulate your immune system to fight the cancer. It is for people with head and neck cancer who have not been helped by prior treatments or who are scheduled for surgery.
Stanford, CaliforniaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06722183RecruitingPhase 2
Futibatinib plus chemo-immunotherapy for advanced colorectal cancer
This trial tests a new combination of drugs (futibatinib plus chemo-immunotherapy) for people with advanced colorectal cancer who have not had prior treatment. It aims to see if this combination can shrink tumors or slow their growth.
AmbergAges 18 years+ - NCT06719362RecruitingPhase 1
Testing a new cancer drug alone and with other therapies
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Portland, OregonAges 18 years+ - NCT06725173Recruiting
Retinoblastoma genetics and tumor spread study
This study looks at gene changes in retinoblastoma to understand why some tumors spread outside the eye. It may help find better ways to predict and treat the disease.
Seattle, WashingtonAges Any age - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Los Angeles, CaliforniaAges 18–90 - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06705049Enrolling by invitation
Study on cancer spread to the lining of the brain
This study looks at how solid tumors spread to the lining of the brain and spinal cord. It aims to understand this condition better by reviewing patient records.
ShanghaiAges 18–80 - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT06667544RecruitingPhase 1/Phase 2
Study of RNK08954 for advanced cancers with KRAS G12D mutation
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
Nanning, GuangxiAges 18 years+ - NCT06654011RecruitingPhase 2
A study testing a new combination for rare cervical cancer
This trial tests whether adding the drug IN10018 to a standard chemotherapy and immunotherapy combination can help treat a rare type of cervical cancer called gastric-type adenocarcinoma that has spread or come back. The goal is to see if this combination improves outcomes for patients who have already had at least one round of chemotherapy.
Wuhan, HubeiAges 18–75 - NCT06639256RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug called HY07121 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
JinanAges 18–80 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06603987Enrolling by invitationPhase 1/Phase 2
Testing a new drug combination for recurrent solid tumors
This early-phase trial tests a new combination of drugs (CICS-1 and SPM-011) along with a special imaging scan to see if they can help people with hard-to-treat cancers that have come back. It may be an option if standard treatments are no longer working.
Osaka, OsakaAges 18–85
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.